Document:

<PAGE>

                                                                    EXHIBIT 4.38

         AMENDMENT NO. 8 TO NOTE AND PREFERRED STOCK PURCHASE AGREEMENT

         THIS AMENDMENT NO. 8 TO NOTE AND PREFERRED STOCK PURCHASE AGREEMENT
(this "Amendment") is made as of April __, 2003, by and among EpicEdge, Inc., a
Texas corporation (the "Company"), and Edgewater Private Equity Fund III, L.P.,
a Delaware limited partnership ("Edgewater").

         WHEREAS, the Company, Edgewater and certain other parties named therein
entered into that certain Note and Preferred Stock Purchase Agreement dated as
of April 16, 2002 (as amended from time to time, the "Purchase Agreement");

         WHEREAS, pursuant to Section 9.5 of the Purchase Agreement, the
Purchase Agreement may be amended by the Company and the Purchaser Majority (as
defined therein); and

         WHEREAS, the Company and the Purchaser Majority wish to amend the
Purchase Agreement pursuant to the terms set forth herein.

         NOW, THEREFORE, for and in consideration of the premises and mutual
agreements herein contained and for the purposes of setting forth the terms and
conditions of this Amendment, the parties, intending to be bound, hereby agree
as follows:

         1.       Incorporation of the Agreement. All capitalized terms which
are not defined hereunder shall have the same meanings as set forth in the
Purchase Agreement. To the extent any terms and provisions of the Purchase
Agreement are inconsistent with the amendments set forth in Paragraph 2 below,
such terms and provisions shall be deemed superseded hereby. Except as
specifically set forth herein, the Purchase Agreement shall remain in full force
and effect and its provisions shall be binding on the parties hereto.

         2.       Amendments to the Purchase Agreement.

                  (a)      The definition of Repayment Date set forth in Section
2.5 of the Purchase Agreement shall be amended to mean January 31, 2006.

                  (b)      Section 2.7 of the Purchase Agreement is hereby
amended and restated in its entirety to read as follows:

                           2.7      Conversion. At the Equity Closing, the
                  Outstanding Balance payable to each Lender shall be converted
                  by each Lender into shares of Series B Stock at a conversion
                  price equal to the Original Series B Purchase Price, other
                  than the unpaid portion of the Edgewater Special Debt, plus
                  accrued interest thereon, which amount shall, in the sole
                  discretion of Edgewater, be either (a) repaid in accordance
                  with the terms of the applicable Substitute Note, or (b) at
                  any time on or after the Equity Closing, but prior to the
                  Repayment Date, be converted into shares of Series B-1

<PAGE>

                  Convertible Preferred Stock, par value $0.01 per share, of the
                  Company at a conversion price equal to $0.75 per share.

         3.       Effectuation. The amendments to the Purchase Agreement
contemplated by this Amendment shall be deemed effective immediately upon the
full execution of this Amendment and without any further action required by the
parties hereto. There are no conditions precedent or subsequent to the
effectiveness of this Amendment.

         4.       Fees and Expenses. The Company agrees to pay on demand all
costs and expenses of or incurred by Edgewater (including, but not limited to,
legal fees and expenses) in connection with the evaluation, negotiation,
preparation, execution and delivery of this Amendment.

         5.       Counterparts. This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument. One or more counterparts
of this Amendment may be delivered by facsimile, with the intention that
delivery by such means shall have the same effect as delivery of an original
counterpart thereof.

                            [SIGNATURE PAGE FOLLOWS]

                                    * * * * *

                                        2

<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Amendment No. 8 to
Note and Preferred Stock Purchase Agreement as of the date first written above.

EpicEdge, Inc.
(d/b/a EpicEdge), a Texas corporation

By: /s/ Robert A. Jensen
   ---------------------------------
   Robert A. Jensen
   COO, CFO and Secretary

Edgewater Private Equity Fund III, L.P., a Delaware
limited partnership

By:  Edgewater III Management, L.P.
Its: General Partner

By:  Edgewater III, Inc.
Its: General Partner

By: /s/ Mark McManigal
   ---------------------------------
Its: Partner
    --------------------------------<PAGE>

                                                                    EXHIBIT 4.39

THIS SUBSTITUTE CONVERTIBLE SECURED PROMISSORY NOTE HAS NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID
ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO EPICEDGE, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

                 SUBSTITUTE CONVERTIBLE SECURED PROMISSORY NOTE

$2,000,000                                                     Chicago, Illinois
                                                                   April 4, 2003

         FOR VALUE RECEIVED, EpicEdge, Inc., a Texas corporation (the
"Company"), promises to pay to the order of Edgewater Private Equity Fund III,
L.P., a Delaware limited partnership ("Holder"), the principal sum of Two
Million Dollars ($2,000,000), and to pay interest on the outstanding principal
balance of this Substitute Convertible Secured Promissory Note (this "Note") in
accordance with Section 2 of this Note. This Note is delivered in connection
with that certain Note and Preferred Stock Purchase Agreement dated as of April
16, 2002 (as may be amended, restated or otherwise modified from time to time,
the "Purchase Agreement") between the Company, the Holder and certain other
parties named therein. Capitalized terms not otherwise defined herein shall have
the meanings set forth in the Purchase Agreement. This Note is and shall
constitute a Substitute Note under the Purchase Agreement.

1.       Maturity. To the extent not previously converted in accordance with
         Section 4 hereof, the Company shall repay the outstanding principal
         balance of this Note and interest accrued thereon in full on January
         31, 2006 (the "Maturity Date"). All payments received shall be applied
         first against costs of collection (if any), then against accrued and
         unpaid interest on this Note, then against the outstanding principal
         balance of this Note.

2.       Interest. Interest shall begin to accrue on the outstanding principal
         balance of this Note commencing on the date hereof (in addition to all
         interest previously accrued hereunder) and continuing until repayment
         of this Note in full at the rate of four percent (4%) per annum
         calculated on the basis of a 360 day year and actual days elapsed.
         However, upon the occurrence of a Default (as defined herein) the
         interest on the outstanding principal balance of this Note will accrue
         from the date of such Default until such time as such Default is cured
         in a manner that is acceptable to the Holder at a rate per annum equal
         to three percent (3%) plus the interest rate then in effect.

3.       Prepayment; Acceleration. The outstanding principal balance and all
         accrued interest payable to Holder hereunder may not be prepaid without
         the consent of Holder in its sole and absolute discretion. All
         prepayments so permitted by Holder shall be applied in the order
         provided in Section 1. The outstanding principal balance of this Note
         plus accrued

<PAGE>

         interest thereon shall become immediately due and payable upon the
         occurrence of a Default (as defined herein). Following any such
         acceleration, Holder may pursue any and all legal or equitable remedies
         that are available to it.

4.       Conversion. Prior to the Maturity Date, Holder may, in its sole and
         absolute discretion, convert the outstanding principal balance of this
         Note and the accrued but unpaid interest thereon into shares of Series
         B-1 Convertible Preferred Stock, par value $0.01 per share, of the
         Company ("Series B-1 Stock") at a conversion price equal to $0.75 per
         share.

5.       Authorization of Series B-1 Stock. On or prior to the date hereof, the
         Company shall designate, authorize and create 5,000,000 shares of
         Series B-1 Stock having the designation, powers, preferences and rights
         and the qualifications, limitations or restrictions thereof set forth
         in the Amended and Restated Articles of Incorporation of the Company
         attached hereto as Exhibit A (the "Articles"). In addition, on or prior
         to the date hereof, the Company shall amend and restate the rights,
         preferences and designations of the Series A Stock and Series B Stock
         as set forth in the Articles.

6.       Purchase and Sale of the Warrant. On the date hereof, in connection
         with certain loans and other financial accommodations provided by
         Holder to the Company, the Company shall issue to Holder (a) a warrant
         to purchase 1,333,333 shares of Series B-1 Stock for an exercise price
         of $0.01 per share, and (b) a warrant to purchase 200,000 shares of
         Series B-1 Stock for an exercise price of $0.01 per share
         (collectively, the "Warrants"), each containing the terms and
         conditions set forth in the form of warrant attached hereto as Exhibit
         B.

7.       Amendment to Registration Agreement. In order to provide Holder with
         the registration rights provided for under that certain Registration
         Rights Agreement dated as of February 18, 2000, as amended by that
         certain Registration Rights Agreement dated as of September 29, 2000,
         as further amended by that certain Amendment to Registration Agreement
         dated as of April 16, 2002 (the "Existing Registration Agreement") for
         the Common Stock issuable upon conversion of the Series B-1 Stock (the
         "Conversion Stock"), on the date hereof the Company and Holder shall
         enter into an Amendment to Registration Agreement containing the terms
         and conditions set forth in the form of Amendment to Registration
         Agreement attached hereto as Exhibit C (the Existing Registration
         Agreement as amended by such Amendment to Registration Agreement shall
         be referred to herein as the "Registration Agreement;" and, together
         with this Note, the Warrants and the Articles, the "Series B-1
         Documents").

8.       Secured Obligation. The outstanding principal amount of this Note and
         all accrued interest thereon and all other obligations of the Company
         hereunder are secured by a perfected security interest in all of the
         Company's assets pursuant to the Security Agreement, the Trademark and
         License Security Agreement and the UCC Financing Statement filed with
         the Secretary of State of Texas.

9.       Representations and Warranties. The Company hereby makes the following
         representations and warranties to Holder as of the date hereof, which
         representations and

<PAGE>

         warranties shall survive the execution and delivery of this Note and
         the issuance of the Series B-1 Stock, the Conversion Stock and the
         Warrants:

         (a)      Organization and Qualification. The Company is a corporation
                  duly organized, validly existing and in good standing under
                  the laws of the State of Texas. The Company has all licenses,
                  permits and authorizations necessary to own its properties and
                  to carry on its businesses as now being conducted and as
                  presently proposed to be conducted and is duly qualified to do
                  business as a foreign corporation in each state or country, if
                  any, in which failure to qualify would have a material adverse
                  effect on the financial condition, business, operating
                  results, operations, business prospects or property of the
                  Company.

         (b)      Corporate Power. Except as set forth on the Disclosure
                  Schedule attached to this Note as Exhibit D (the "Disclosure
                  Schedule"), the Company has the requisite corporate power and
                  authority to execute, deliver and carry out the Series B-1
                  Documents and all other instruments, documents and agreements
                  contemplated or required by the provisions of any of the
                  Series B-1 Documents to be executed, delivered or carried out
                  by the Company thereunder. The Company has all requisite
                  corporate power and authority under the laws of its
                  jurisdiction of incorporation to own and operate its
                  properties and to carry on its businesses as now conducted and
                  as presently proposed to be conducted.

         (c)      Authorization, Governmental Approvals. Except as set forth on
                  the Disclosure Schedule, the execution and delivery of this
                  Note, the issuance of the Series B-1 Stock, the issuance of
                  the Conversion Stock, the issuance of the Warrants, the
                  execution and delivery of the other Series B-1 Documents and
                  all other instruments, documents and agreements contemplated
                  or required by the provisions hereof or thereof to be executed
                  and delivered by the Company, and the consummation by the
                  Company of the transactions herein and therein contemplated to
                  be consummated by the Company have each been duly authorized
                  by all necessary corporate action on the part of the Company.
                  Except for filings necessary for the sale of the Warrants,
                  this Note, the Series B-1 Stock issuable upon the exercise of
                  the Warrants and conversion of this Note and the Conversion
                  Stock to qualify for certain exemptions from the registration
                  requirements under state blue sky laws and federal securities
                  laws, no authorization, consent, approval, license or
                  exemption of, and no registration, qualification, designation,
                  declaration or filing with, any court or governmental
                  department, commission, board, bureau, agency or
                  instrumentality, domestic or foreign, and no vote,
                  authorization, consent or approval of shareholders of the
                  Company, other than the required shareholder vote to authorize
                  and file the Articles, is or was necessary for (i) the valid
                  execution and delivery of this Note by the Company, (ii) the
                  execution, issuance and delivery of the Series B-1 Stock, the
                  Warrants and the issuance of the Conversion Stock hereunder or
                  thereunder, (c) the execution and delivery by the Company of
                  the other Series B-1 Documents and all other instruments,
                  documents and agreements contemplated or required by the
                  provisions hereof or thereof and to be executed and delivered
                  by the

<PAGE>

                  Company, or (d) the consummation by the Company of the
                  transactions herein and therein contemplated to be consummated
                  by the Company.

         (d)      Capital Stock. The Series B-1 Stock issuable upon conversion
                  of this Note, the exercise of the Warrants and the Conversion
                  Stock when issued in accordance with the terms of this Note,
                  the Warrants and the Articles will be duly and validly
                  reserved for issuance, and upon issuance thereof will be duly
                  and validly issued, fully paid, and nonassessable, and except
                  for restrictions pursuant to the Shareholders' Agreement, will
                  be free of restrictions on transfer other than the
                  restrictions on transfer under the applicable state and
                  federal securities laws.

         (e)      Conflict with Other Instruments. Except as set forth on the
                  Disclosure Schedule, neither the execution and delivery by the
                  Company of the Series B-1 Documents or the other instruments,
                  documents and agreements contemplated or required hereby or
                  thereby, nor the consummation of the transactions herein or
                  therein contemplated to be consummated by the Company, nor
                  compliance by the Company with the terms, conditions and
                  provisions hereof or thereof, shall conflict with or result in
                  a breach of any of the terms, conditions or provisions of the
                  Articles of Incorporation or the Bylaws of the Company, or any
                  law or any regulation, order, writ, injunction or decree of
                  any court or governmental instrumentality or any agreement or
                  instrument to which the Company is a party or by which it or
                  any of its respective properties is bound or constitute a
                  default thereunder or result in the creation or imposition of
                  any Lien, except for those Liens being created by or granted
                  pursuant to the Security Agreement. The three-year moratorium
                  on certain business combinations as set forth in Section 13.03
                  of the Texas Business Corporation Act is inapplicable to the
                  transactions contemplated herein.

         (f)      Validity and Binding Effect. Except as set forth on the
                  Disclosure Schedule, the Series B-1 Documents which the
                  Company is required to execute and all other instruments and
                  agreements contemplated hereby or thereby to which the Company
                  is a party have been duly and validly executed and delivered
                  by the Company and constitute legal, valid and binding
                  obligations of the Company, and all such obligations of the
                  Company are enforceable in accordance with their respective
                  terms.

         (g)      Capitalization.

                  (i)      As of the date of this Note, the authorized capital
                           stock of the Company consists of (A) 100,000,000
                           shares of Common Stock, of which 18,200,333 shares
                           are issued and outstanding, and (B) 30,000,000 shares
                           of preferred stock of the Company of which (1)
                           10,000,000 are designated as Series A Stock of which
                           9,695,481 shares are issued and outstanding, (2)
                           10,000,000 are designated as Series B Stock of which
                           3,173,451 shares are issued and outstanding, (3)
                           5,000,000 are designated as Series B-1 Stock, none of
                           which are outstanding, and (4) 5,000,000 are
                           remaining undesignated blank check preferred none of
                           which are issued and

<PAGE>

                           outstanding. All of the outstanding shares of capital
                           stock of the Company are validly issued, fully paid
                           and nonassessable and are owned of record or
                           beneficially by the Company's shareholders. Except as
                           set forth on the Disclosure Schedule or on Schedule
                           3.8.b of the Disclosure Schedules to the Purchase
                           Agreement there are not outstanding any shares of
                           stock, securities, rights or options convertible or
                           exchangeable into or exercisable for any shares of
                           the Company's capital stock, stock appreciation
                           rights or phantom stock, nor is the Company under any
                           obligation (contingent or otherwise) to redeem or
                           otherwise acquire any shares of its capital stock or
                           any securities, rights or options to acquire such
                           capital stock, stock appreciation rights or phantom
                           stock. There are no statutory or contractual
                           shareholders preemptive rights with respect to any
                           shares of capital stock of the Company. The Company
                           has not violated and will not violate any applicable
                           federal or state securities laws in connection with
                           the offer, sale or issuance of the Series B-1 Stock,
                           the Conversion Stock, the Warrants and this Note and
                           such issuances, offers, or sales do not require
                           registration of such Securities under the Securities
                           Act or any applicable state securities laws. Except
                           as set forth on Schedule 3.8.c of the Disclosure
                           Schedule to the Purchase Agreement, and for the
                           Shareholders' Agreement, the Voting Agreement and the
                           Registration Agreement, to the Company's knowledge,
                           there are no agreements between the Company's
                           shareholders (or any one or more of them) with
                           respect to the voting or transfer of the Company's
                           capital stock or with respect to any other aspect of
                           the Company's affairs.

10.      Holder Investment Representations. Holder hereby makes the
         representation and warranties set forth in Section 4 of the Purchase
         Agreement as of the date hereof.

11.      Covenants. So long as (a) any shares of Series B-1 Stock issued
         hereunder are outstanding, (b) Holder or its Affiliates own of record
         or beneficially at least 500,000 shares of Common Stock, or (c) Holder
         holds any portion of the outstanding principal amount of this Note, the
         covenants set forth in Section 6 (except for Sections 6.7, 6.8, and
         6.9) of the Purchase Agreement shall be incorporated herein such that
         Holder shall be entitled to the benefits thereof and neither the
         Company nor any Subsidiary shall, without the prior written consent of
         the Holder do any of the actions set forth in Section 6.3 of the
         Purchase Agreement. This Section 11 shall survive the execution and
         delivery of this Note and the issuance of the Series B-1 Stock, the
         Conversion Stock and the Warrants.

12.      Default. The Company will be deemed to be in default ("Default")
         hereunder upon (a) the occurrence of any "Event of Default" described
         in Section 7.1 (except for Sections 7.1(k)) of the Purchase Agreement;
         provided that if any Event of Default has been waived pursuant to
         Section 7.1 of the Purchase Agreement, such waived Event of Default
         shall not constitute an Event of Default hereunder or (b) a breach or
         default of any of the Company's representations, warranties, covenants
         and agreements under this Note or the other Series B-1 Documents (which
         continues beyond the expiration of any

<PAGE>

         applicable cure period), and Holder shall have all rights and remedies
         available to it upon any such Default as described in the Purchase
         Agreement or in this Note.

13.      Miscellaneous.

         (a)      The Company hereby waives presentment, demand, protest, notice
                  of dishonor, diligence and all other notices, any release or
                  discharge arising from any extension of time, discharge of a
                  prior party, or other cause of release or discharge other than
                  actual payment in full hereof.

         (b)      Holder shall not be deemed, by any act or omission, to have
                  waived any of its rights or remedies hereunder unless such
                  waiver is in writing and signed by Holder and then only to the
                  extent specifically set forth in such writing. A waiver with
                  reference to one event shall not be construed as continuing or
                  as a bar to or waiver of any right or remedy as to a
                  subsequent event. No delay or omission of Holder to exercise
                  any right, whether before or after a Default hereunder, shall
                  impair any such right or shall be construed to be a waiver of
                  any right or Default, and the acceptance at any time by Holder
                  of any past-due amount shall not be deemed to be a waiver of
                  the right to require prompt payment when due of any other
                  amounts then or thereafter due and payable.

         (c)      Time is of the essence hereof. Upon any Default hereunder,
                  Holder may exercise all rights and remedies provided for
                  herein or in the Purchase Agreement and by law or equity,
                  including, but not limited to, the right to immediate payment
                  in full of this Note.

         (d)      The remedies of Holder as provided herein or in the Purchase
                  Agreement, or any one or more of them, in law or at equity,
                  shall be cumulative and concurrent, and may be pursued
                  singularly, successively or together at Holder's sole
                  discretion, and may be exercised as often as occasion therefor
                  shall occur.

         (e)      It is expressly agreed that if this Note is referred to any
                  attorney or if suit is brought to collect or interpret this
                  Note or any part hereof or to enforce or protect any rights
                  conferred upon Holder by this Note or any other document
                  evidencing or securing this Note, then the Company covenants
                  and agrees to pay all reasonable costs, including attorneys'
                  fees, incurred by Holder in connection therewith.

         (f)      If any provisions of this Note would require the Company to
                  pay interest hereon at a rate exceeding the highest rate
                  allowed by applicable law, the Company shall instead pay
                  interest under this Note at the highest rate permitted by
                  applicable law.

         (g)      This Note shall be governed by and construed in accordance
                  with the laws of the State of Illinois without giving effect
                  to any choice or conflict of law provision or law that would
                  cause the application of the laws of any other jurisdiction
                  other than the State of Illinois.

<PAGE>

         (h)      This Note may be amended, modified or supplemented only by a
                  written instrument duly executed by Holder and the Company. If
                  any provision of this Note shall for any reason be held to be
                  invalid, illegal, or unenforceable in any respect, such
                  invalidity, illegality, or unenforceability shall not affect
                  any other provision hereof, and this Note shall be construed
                  as if such invalid, illegal or unenforceable provision had
                  never been contained herein. This Note shall be binding upon
                  and inure to the benefit of and be enforceable by the
                  respective heirs, legal representatives, successors and
                  permitted assigns of the parties. Nothing in this Note shall
                  confer any rights upon any person other than the parties
                  hereto and their respective heirs, legal representatives,
                  successors and permitted assigns. The Company may assign this
                  Note without the prior written consent of Holder.

         (i)      This Note is issued in substitution for but not in payment of
                  the Prior Note and does not and shall not be deemed to
                  constitute a novation thereof. Such Prior Note shall be of no
                  further force and effect upon the execution of this Note;
                  provided, however, that the outstanding amount of principal
                  and interest under the Prior Note as of the date of this Note
                  is hereby deemed indebtedness evidenced by this Note and
                  incorporated herein by this reference.

         (j)      The Company agrees to pay on demand all costs and expenses of
                  or incurred by Holder (including, but not limited to, legal
                  fees and expenses) in connection with the evaluation,
                  negotiation, preparation, execution and delivery of this Note
                  and the other Series B-1 Documents.

                            [SIGNATURE PAGE FOLLOWS]

<PAGE>

IN WITNESS WHEREOF, the Company has executed this Substitute Convertible Secured
Promissory Note as of the date first above written.

                                           EPICEDGE, INC.
                                           (d/b/a EpicEdge), a Texas corporation

                                            By: /s/ Robert A. Jensen
                                                --------------------
                                                Robert A. Jensen
                                                COO, CFO and Secretary

AGREED AND ACCEPTED as of April 4, 2003 by:

EDGEWATER PRIVATE EQUITY FUND III, L.P.

By:  Edgewater III Management, L.P.
Its: General Partner

By:  Edgewater III, Inc.
Its: General Partner

By: /s/ Mark McManigal
    ------------------
Its: Partner

<PAGE>

                                    EXHIBIT A

                 AMENDED AND RESTATED ARTICLES OF INCORPORATION

                                  See Attached.

<PAGE>

                                    EXHIBIT B

                                 FORM OF WARRANT

                                  See Attached.

<PAGE>

                                    EXHIBIT C

                       AMENDMENT TO REGISTRATION AGREEMENT

                                  See Attached.

<PAGE>

                                    EXHIBIT D

                               DISCLOSURE SCHEDULE

                                  See Attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]